Valuation: Avicanna Inc.

Market Cap 18.14M 13.07M 11.29M 10.61M 9.65M 1.25B 18.44M 124M 48.61M 626M 49.08M 48.02M 2.08B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 17.86M 12.87M 11.12M 10.45M 9.5M 1.23B 18.16M 122M 47.86M 616M 48.32M 47.27M 2.05B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.18%
Yield 2024 *
-
Yield 2025 -
1 day+3.85%
Current month+8.00%
1 month+3.85%
3 months-3.57%
6 months-20.59%
Current year-40.00%
1 week 0.12
Extreme 0.125
0.14
1 month 0.12
Extreme 0.12
0.14
Current year 0.1
Extreme 0.095
0.24
1 year 0.1
Extreme 0.095
0.3
3 years 0.1
Extreme 0.095
0.6
5 years 0.1
Extreme 0.095
1.01
10 years 0.1
Extreme 0.095
7.4
Manager TitleAgeSince
Sales & Marketing - 2015-04-30
Chief Executive Officer 39 2016-11-25
Director of Finance/CFO - 2025-09-14
Director TitleAgeSince
Chairman 39 2016-11-25
Director/Board Member - 2018-10-21
Director/Board Member - 2025-12-31
Date Insider Type Main position Quantity % Market Cap.
6/12/26 Sell

Director

333,000 0.2647%
5/6/26 BuyCompany -48,500 0.0386%
4/25/26 BuyCompany 196,500 0.1563%
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%0.00%-50.00%-51.79% 13.07M
-1.78%-1.68%+1.48%+17.26% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
+0.49%+0.92%+4.11%+26.37% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -0.21%-0.04%+63.79%+98.55% 26.32B
Weighted average by Cap. -0.91%-0.11%+95.82%+140.25%

Financials

2024 2025
Net sales 25.46M 18.35M 15.85M 14.89M 13.54M 1.75B 25.88M 174M 68.21M 878M 68.88M 67.39M 2.92B 25.48M 18.36M 15.86M 14.9M 13.55M 1.76B 25.9M 175M 68.27M 879M 68.93M 67.44M 2.92B
Net income -3.62M -2.61M -2.25M -2.12M -1.92M -249M -3.68M -24.79M -9.69M -125M -9.79M -9.58M -415M -2.76M -1.99M -1.72M -1.61M -1.47M -190M -2.8M -18.91M -7.39M -95.21M -7.47M -7.3M -316M
Net Debt -339K -244K -211K -198K -180K -23.35M -344K -2.32M -908K -11.69M -917K -897K -38.85M -281K -202K -175K -164K -149K -19.34M -285K -1.92M -752K -9.68M -759K -743K -32.18M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
26-08-14 $0.1350 +3.85% 47,033
26-08-13 $0.1300 0.00% 39,050
26-08-12 $0.1300 0.00% 150,040
26-08-11 $0.1300 0.00% 91,142
26-08-10 $0.1300 -3.70% 119,530
  1. Stock Market
  2. Stocks
  3. AVCN Stock